DEVELOPMENTS FOR DRY EYE DISEASE

Bausch + Lomb + Lamb have announced their topline results from their first Phase 3 trial of NOV03 – a first-in-class eye drop with the novel mechanism of action to treat the signs and symptoms of dry eye disease linked to Meibomian Gland Dysfunction.

Dry eye disease is a common ocular problem, affecting at least 16 million people in America, meanwhile Meibomian Gland Dysfunction accounts for 86% of dry eyes. The Phase 3 trial is showing statistically significant improvements in both the signs and symptoms of dry eye disease.

“The rapid onset of action and statistical significance demonstrated in this trial is impressive. It also gets us a step closer to bringing forward this potential first-in-class treatment option, which could be a promising development for millions of patients.” Joseph Papa, chairman and CEO, Bausch Health.

Ref: https://www.novaliq.com/press-releases/2021/04/13/partner-bausch-lomb-announces-statistically-significant-topline-results-from-the-first-phase-3-trial-of-nov03/